Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | May 26, 2022 | May 31, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date May 26, 2022 · Filed May 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,244 |
Reported balance
After 2022-05-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 8,446 · Balance 40,244 F1: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.
F2: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2022 Filed May 31, 2022 16:20 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-22-000092 · wf-form4_165402841193936.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,244 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 20, 2021 Filed May 24, 2021 17:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000089 · wf-form4_162189019421132.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,798 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 16:52 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,000 | $124.11 | $744,635.40 |
DisclosureSEC source: 0001367644-20-000134 · wf-form4_159726555510283.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,771 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $121.78 to $125.14. Read SEC document |
| May 21, 2020 Filed May 26, 2020 09:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000076 · wf-form4_159049855700385.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,771 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 11, 2020 Filed May 13, 2020 19:45 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,000 | $85.19 | $170,371.20 |
DisclosureSEC source: 0001367644-20-000061 · wf-form4_158941353141255.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,950 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.1600 to $85.2200, inclusive. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012272 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,950 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 16:36 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 4,058 | $68.45 | $277,784.30 |
DisclosureSEC source: 0001567619-18-005434 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,214 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.4275 to $68.5062, inclusive. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 16:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,000 | $52.89 | $264,447.50 |
DisclosureSEC source: 0001140361-18-028232 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,272 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.73 to $53.125, inclusive. Read SEC document |
| May 24, 2018 Filed May 24, 2018 18:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 4,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025562 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,272 F1 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the day prior to the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 16:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Option (Right to buy) · Derivative | 10,305 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001140361-17-041866 · doc1.xml · derivative · entry 6 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,305 shares Expires 2021-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 16:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Option (Right to buy) · Derivative | 3,946 | $0.00 Strike: $15.97 | $0.00 |
DisclosureSEC source: 0001140361-17-041866 · doc1.xml · derivative · entry 5 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,946 shares Expires 2020-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 16:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 10,305 | $41.24 | $424,978.20 |
DisclosureSEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 4 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,377 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.45, inclusive. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 16:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 10,305 | $18.64 | $192,085.20 |
DisclosureSEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 3 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 16:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,946 | $41.24 | $162,733.04 |
DisclosureSEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 2 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,377 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.45, inclusive. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 16:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,946 | $15.97 | $63,017.62 |
DisclosureSEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 26, 2017 13:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022459 · doc1.xml · nonDerivative · entry 4 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,377 F4 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F5 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| August 01, 2016 Filed May 26, 2017 13:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 905 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001140361-17-022459 · doc1.xml · derivative · entry 6 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,305 Underlying: Common Stock · 10,305 shares Expires 2021-05-22 F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F8 · derivative.exercise_date: The option grant vests in May 2017. Read SEC document |
| August 01, 2016 Filed May 26, 2017 13:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 346 | $0.00 Strike: $15.97 | $0.00 |
DisclosureSEC source: 0001140361-17-022459 · doc1.xml · derivative · entry 5 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,946 Underlying: Common Stock · 3,946 shares Expires 2020-07-17 F6 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F7 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| August 01, 2016 Filed May 26, 2017 13:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022459 · doc1.xml · nonDerivative · entry 3 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,118 F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019. Read SEC document |
| August 01, 2016 Filed May 26, 2017 13:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022459 · doc1.xml · nonDerivative · entry 2 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,541 F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018. Read SEC document |
| August 01, 2016 Filed May 26, 2017 13:22 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 152 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022459 · doc1.xml · nonDerivative · entry 1 JOULWAN GEORGE A · CIK 0001222197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,937 F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.